Talquetamab shows promise in multi-drug refractory multiple myeloma patients
New Phase I data shows 65 percent of triple-class and…
New Phase I data shows 65 percent of triple-class and 83 percent of penta-drug refractory multiple myeloma patients responded to talquetamab.